Back to results
US 2021/0079080 A1Published application
Anti-vegf anitbodies and methods of use
AssigneeHoffmann-La Roche Inc.
InventorsStefan Dengl, Sebastian Fenn, Guy Georges, Joerg Moelleken, Francesca Ros, Esther Koenigsberger
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-VEGF antibodies and methods of their production and their use.
Claims26
The antibody of claim 2,
- a) wherein binding of the antibody to VEGF significantly inhibits VEGF-binding to VEGF receptor VEGF-R2 without significantly inhibiting VEGF-binding to VEGF receptor VEGF-R1, and
- b) wherein the antibody binds VEGF with an affinity of ≤150 pM as measured by surface plasmon resonance at a temperature of 25° C. and as measured by surface plasmon resonance at a temperature of 37° C.
An antibody that binds to VEGF, wherein the antibody comprises
- a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:03;
- (ii) CDR-H2 having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:04;
- and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:05;
- and
- b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:06;
- (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:07;
- and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:08.
4 more elements
An antibody that binds to VEGF that is an affinity matured variant of an antibody having a VH sequence of SEQ ID NO:
- 01 and a VL sequence of SEQ ID NO:
- 02.
An antibody that binds to VEGF, wherein the antibody binds to the same epitope as an antibody having a VH sequence of SEQ ID NO:
- 01 and a VL sequence of SEQ ID NO:
- 02.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.